Evoke Pharma Inc (EVOK)

1.63
0.16 8.90
NASDAQ : Health Care
Prev Close 1.79
Open 1.78
Day Low/High 1.65 / 1.78
52 Wk Low/High 1.72 / 11.11
Volume 165.18K
Avg Volume 316.50K
Exchange NASDAQ
Shares Outstanding 7.24M
Market Cap 13.47M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Evoke Pharma (EVOK) Stock Plummets After Late-Stage Trial Miss

Evoke Pharma (EVOK) Stock Plummets After Late-Stage Trial Miss

Evoke Pharma’s (EVOK) diabetic gastroparesis drug missed its primary endpoint in phase 3 topline results.

Evoke Pharma Presents Data From Successful Thorough ECG (TQT) Study Of EVK-001 At Digestive Disease Week 2016

Evoke Pharma Presents Data From Successful Thorough ECG (TQT) Study Of EVK-001 At Digestive Disease Week 2016

Further Safety of EVK-001 Demonstrated with TQT Results

Evoke Pharma Reports Fourth Quarter And Year End 2015 Results

Evoke Pharma Reports Fourth Quarter And Year End 2015 Results

Provides Outlook for Completing Phase 3 Clinical Trial and Upcoming NDA Submission

Evoke Accelerates New Drug Application Process By Engaging Regulatory Experts

Evoke Accelerates New Drug Application Process By Engaging Regulatory Experts

NDA Preparation Initiates as EVK-001 Nears Phase 3 Study Completion

Evoke Nears Completion Of Phase 3 Clinical Trial Enrollment And Secures Extension To Credit Facility

Evoke Nears Completion Of Phase 3 Clinical Trial Enrollment And Secures Extension To Credit Facility

186 of 200 Subjects Enrolled in Phase 3 Clinical Trial of EVK-001

Evoke Pharma Reports Third Quarter 2015 Results

Evoke Pharma Reports Third Quarter 2015 Results

Enhanced Financial Strength and Further Progressed Trial Enrollment

Evoke Pharma Strengthens Financial Position

Evoke Pharma Strengthens Financial Position

Provides Additional Support for Completion of Phase 3 Trial and Submission of New Drug Application (NDA)

Evoke Reaches Study Enrollment Milestone Associated With Credit Facility

Evoke Reaches Study Enrollment Milestone Associated With Credit Facility

150 Patients Enrolled in Phase 3 Clinical Trial

U.S. Food And Drug Administration's (FDA) Draft Guidance Is Consistent With Evoke's Current Phase 3 Study Design And Endpoint For EVK-001

U.S. Food And Drug Administration's (FDA) Draft Guidance Is Consistent With Evoke's Current Phase 3 Study Design And Endpoint For EVK-001

States Patients With Diabetic Gastroparesis May Have Unpredictable Gastric Emptying and Altered Absorption of Orally-Administered Hypoglycemic Drugs

Evoke Pharma Announces Publication Of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms In Women With Diabetic Gastroparesis

Evoke Pharma Announces Publication Of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms In Women With Diabetic Gastroparesis

Second Phase 2 Trial Demonstrates Effectiveness of Intranasal Metoclopramide Spray

Evoke Pharma Reports First Quarter 2015 Results

Evoke Pharma Reports First Quarter 2015 Results

Company Begins Preparation for Commercialization of EVK-001